Video Insights
Advertisement
Karun Neupane, MD, discusses why the meeting was a valuable experience for him as a first-time attendee.
Myelofibrosis Awareness Day is marked on September 20th each year.
The panel discussed the FDA-approved bispecific agents for myeloma and how the options performed in clinical trials.
In the first segment of the roundtable series, the panel discussed the latest CAR-T data, including KarMMa-3 and CARTITUDE-4.
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
Swaminathan Iyer, MD, joins Chadi Nabhan, MD, MBA, FACP, to discuss advances in T-cell lymphoma.
Advertisement
Alessandra Ferrajoli, MD, discusses her presentation on the topic during the Eleventh Annual Meeting of SOHO.
Dr. Anderson spoke about her plenary session on the topic at the Eleventh Annual Meeting of SOHO.
Dr. Nath spoke transplant in patients with AML who are elderly and emphasized the need to include them in clinical trials.
Dr. Komrokji speaks about what might follow the recent FDA approval of luspatercept for certain patients with MDS.
Dr. Cortes speaks about the plenary session he delivered during the Eleventh Annual Meeting of SOHO.
The single-center study was conducted to address gaps in knowledge surrounding minority-predominant populations of patients.
Dr. Platzbecker joins Chadi Nabhan, MD, MBA, FACP, to discuss MDS at the Eleventh Annual Meeting of SOHO.
Dr. Konopleva explains the controversy and what she sees on the horizon for MRD in AML.
Guillermo Garcia-Manero, MD, joins Chadi Nabhan, MD, MBA, FACP, to discuss the COMMANDS trial at the SOHO Annual Meeting.
The meeting will be held September 6-9, 2023, in Houston, Texas.
Ajay Nooka, MD, FACP, discusses the data behind the FDA accelerated approval of elranatamab.
Dr. Nooka, who served as an investigator on the MagnetisMM-3 trial, discusses the impact of the accelerated approval.
In June 2023, a patient death led to the US Food and Drug Administration pausing the iMMagine-1 study.
Dr. Cerchione discusses the importance of ensuring adequate representation in multiple myeloma clinical trials.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.